TY - JOUR
T1 - Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
AU - for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions
AU - Kahn, Jessica A.
AU - Belzer, Marvin
AU - Chi, Xiaofei
AU - Lee, Jeannette
AU - Gaur, Aditya H.
AU - Mayer, Kenneth
AU - Martinez, Jaime
AU - Futterman, Donna C.
AU - Stier, Elizabeth A.
AU - Paul, Mary E.
AU - Chiao, Elizabeth Y.
AU - Reirden, Daniel
AU - Goldstone, Steven E.
AU - Ortiz Martinez, Ana P.
AU - Cachay, Edward R.
AU - Barroso, Luis F.
AU - Da Costa, Maria
AU - Wilson, Craig M.
AU - Palefsky, Joel M.
N1 - Funding Information:
This study was supported by the AIDS Malignancies Consortium (AMC) from the National Cancer Institute (UM1CA121974). The following AMC sites participated in this study: Boston Medical Center (E. Stier), Washington University School of Medicine (L. Ratner, G. Bucher), UCSD Moores Cancer Center (W. Wachsman, E. Cachay, A. Sitapati), Laser Surgery Center (S. Goldstone, D. Worrall), UCSF Medical Center Mount Zion (L. Kaplan, M. Berry, N. Jay, J. Palefsky, M. Rubin), Thomas Street Clinic (E. Chiao), Wake Forest University Health Sciences (L. Barroso, L. Bachmann), and University of Puerto Rico (M. Tirado-Gomez, H. Guiot). This work was also supported by The Adolescent Trials Network for HIV/AIDS Interventions (ATN) from the National Institutes of Health [U01 HD 040533 and U01 HD 040474] through the National Institute of Child Health and Human Development (B. Kapogiannis, L. Serchuck), with supplemental funding from the National Institutes on Drug Abuse (N. Borek) and Mental Health (P. Brouwers, S. Allison). The study was scientifically reviewed by the AMC's Executive Committee and ATN's Therapeutic Leadership Group. Network, scientific and logistical support were provided by the AMC Data Management Center (D. Vena and J. Lynne) and the ATN Coordinating Center (C. Wilson, C. Partlow) at the University of Alabama at Birmingham. Network operations and analytic support were provided by the AMC Data Management Center (D. Vena and J. Lynne), the University of Arkansas for Medical Sciences (J. Lee), and the ATN Data and Operations Center at Westat, Inc. (J. Korelitz, B. Driver). The following ATN sites participated in this study: John H. Stroger Jr. Hospital of Cook County (Martinez, Bojan), Montefiore Medical Center (Futterman, Campos), St. Jude's Children's Research Hospital (Gaur, Dillard), Children's Hospital of Los Angeles (Belzer, Tucker), Baylor College of Medicine (Paul, Head, Chiao), The Fenway Institute (Mayer, Dormitzer), and the University of Colorado, Denver (Reirden, Chambers). The investigators are grateful to the members of the local youth Community Advisory Boards for their insight and counsel and are indebted to the youth who participated in this study. The comments and views of the authors do not necessarily represent the views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Vaccine and HPV Mean Geometric Titers were provided through the Investigator-Initiated Studies Program of Merck & Co., Inc. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck & Co., Inc.
Funding Information:
This work was supported by the AIDS Malignancies Consortium (AMC) from the National Cancer Institute [ UM1CA121974 ] and the Adolescent Trials Network for HIV/AIDS Interventions (ATN) from the National Institutes of Health [ U01 HD 040533 and U01 HD 040474 ] through the National Institute of Child Health and Human Development, with supplemental funding from the National Institutes on Drug Abuse and Mental Health. Vaccine and HPV Mean Geometric Titers were provided through the Investigator-Initiated Studies Program of Merck & Co., Inc.
Funding Information:
Dr. Kahn has received research funding from Merck & Co. for clinical trials of the quadrivalent HPV vaccine in HIV-infected men and women; the trials were NIH-funded and Merck & Co. provided vaccine and immunogenicity testing. Dr. Belzer received research funding from ViiV Healthcare. Dr. Palefsky has received travel support and research support from Merck & Co. and serves on the scientific advisory boards for Agenovir Corporation, Antiva Biosciences, and Ubiome. Dr. Futterman has received program support from Gilead. The remaining authors report no conflicts of interest.
Publisher Copyright:
© 2019 The Authors
PY - 2019/6
Y1 - 2019/6
N2 - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
AB - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
KW - Adolescents
KW - Clinical trials
KW - HIV
KW - Human papillomavirus
KW - Men who have sex with men
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85060700418&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2019.01.002
DO - 10.1016/j.pvr.2019.01.002
M3 - Article
C2 - 30658128
AN - SCOPUS:85060700418
SN - 2666-6790
VL - 7
SP - 52
EP - 61
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -